JP2019517497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517497A5 JP2019517497A5 JP2018562674A JP2018562674A JP2019517497A5 JP 2019517497 A5 JP2019517497 A5 JP 2019517497A5 JP 2018562674 A JP2018562674 A JP 2018562674A JP 2018562674 A JP2018562674 A JP 2018562674A JP 2019517497 A5 JP2019517497 A5 JP 2019517497A5
- Authority
- JP
- Japan
- Prior art keywords
- arn
- hpmcas
- pharmaceutical formulation
- solid dispersion
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 22
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 21
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 20
- 239000007962 solid dispersion Substances 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 229960004103 abiraterone acetate Drugs 0.000 claims description 7
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims description 7
- 239000003862 glucocorticoid Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229920000193 polymethacrylate Polymers 0.000 claims description 4
- 229960005205 prednisolone Drugs 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000006104 solid solution Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172968.6 | 2016-06-03 | ||
| EP16172968 | 2016-06-03 | ||
| PCT/US2017/032815 WO2017209939A1 (en) | 2016-06-03 | 2017-05-16 | Anticancer compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517497A JP2019517497A (ja) | 2019-06-24 |
| JP2019517497A5 true JP2019517497A5 (enExample) | 2020-07-02 |
Family
ID=56148120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562674A Pending JP2019517497A (ja) | 2016-06-03 | 2017-05-16 | 抗癌性組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190216829A1 (enExample) |
| EP (1) | EP3463377A1 (enExample) |
| JP (1) | JP2019517497A (enExample) |
| KR (1) | KR20190015314A (enExample) |
| CN (1) | CN109219437A (enExample) |
| AR (1) | AR108489A1 (enExample) |
| AU (1) | AU2017275396A1 (enExample) |
| BR (1) | BR112018074965A2 (enExample) |
| CA (1) | CA3024872A1 (enExample) |
| CL (1) | CL2018003403A1 (enExample) |
| CO (1) | CO2018012857A2 (enExample) |
| CR (1) | CR20180600A (enExample) |
| EA (1) | EA201892828A1 (enExample) |
| IL (1) | IL263157A (enExample) |
| MA (1) | MA45090A (enExample) |
| MX (1) | MX2018014846A (enExample) |
| NI (1) | NI201800127A (enExample) |
| PE (1) | PE20181925A1 (enExample) |
| PH (1) | PH12018502334A1 (enExample) |
| SG (1) | SG11201809680QA (enExample) |
| TN (1) | TN2018000366A1 (enExample) |
| TW (1) | TW201808287A (enExample) |
| UA (1) | UA124154C2 (enExample) |
| WO (1) | WO2017209939A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66323B1 (sr) | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals Inc | Sastavi protiv raka |
| MX381829B (es) | 2014-12-05 | 2025-03-13 | Aragon Pharmaceuticals Inc | Composiciones anticancerígenas. |
| CZ2016573A3 (cs) | 2016-09-16 | 2018-03-28 | Zentiva, K.S. | Pevná formulace abirateronu acetátu vyráběná technologií fluidní granulace |
| CN109125276A (zh) * | 2017-06-19 | 2019-01-04 | 齐鲁制药有限公司 | 一种醋酸阿比特龙片剂的药物组合物及其制备方法 |
| WO2019155416A2 (en) * | 2018-02-09 | 2019-08-15 | Kashiv Pharma Llc | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens |
| CA3098208A1 (en) | 2018-04-26 | 2019-10-31 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
| WO2021009605A1 (en) * | 2019-07-15 | 2021-01-21 | Shilpa Medicare Limited | Dispersible tablets of abiraterone acetate |
| JP2022091129A (ja) * | 2020-12-08 | 2022-06-20 | 東和薬品株式会社 | 組成物ならびにその製造方法および用途 |
| WO2025174375A1 (en) * | 2024-02-15 | 2025-08-21 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ287434B6 (en) | 1992-03-31 | 2000-11-15 | British Tech Group | Use of steroids, substituted in position 17, steroids functioning as carcinostatics and pharmaceutical preparation containing thereof |
| EP3922629A1 (en) | 2012-06-07 | 2021-12-15 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| JP2016514707A (ja) * | 2013-03-15 | 2016-05-23 | アイシューティカ インク．Ｉｃｅｕｔｉｃａ Ｉｎｃ． | アビラテロン酢酸エステル製剤 |
| EP3102183A1 (en) * | 2014-02-05 | 2016-12-14 | LEK Pharmaceuticals d.d. | Solid pharmaceutical compositions of androgen receptor antagonists |
| TWI718102B (zh) * | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
-
2017
- 2017-05-16 UA UAA201813020A patent/UA124154C2/uk unknown
- 2017-05-16 TN TNP/2018/000366A patent/TN2018000366A1/en unknown
- 2017-05-16 EA EA201892828A patent/EA201892828A1/ru unknown
- 2017-05-16 PE PE2018003138A patent/PE20181925A1/es unknown
- 2017-05-16 CR CR20180600A patent/CR20180600A/es unknown
- 2017-05-16 AU AU2017275396A patent/AU2017275396A1/en not_active Abandoned
- 2017-05-16 CA CA3024872A patent/CA3024872A1/en not_active Abandoned
- 2017-05-16 CN CN201780034086.1A patent/CN109219437A/zh active Pending
- 2017-05-16 JP JP2018562674A patent/JP2019517497A/ja active Pending
- 2017-05-16 KR KR1020187036312A patent/KR20190015314A/ko not_active Ceased
- 2017-05-16 SG SG11201809680QA patent/SG11201809680QA/en unknown
- 2017-05-16 BR BR112018074965-6A patent/BR112018074965A2/pt not_active Application Discontinuation
- 2017-05-16 TW TW106116122A patent/TW201808287A/zh unknown
- 2017-05-16 EP EP17725489.3A patent/EP3463377A1/en not_active Withdrawn
- 2017-05-16 US US16/306,802 patent/US20190216829A1/en not_active Abandoned
- 2017-05-16 MA MA045090A patent/MA45090A/fr unknown
- 2017-05-16 MX MX2018014846A patent/MX2018014846A/es unknown
- 2017-05-16 WO PCT/US2017/032815 patent/WO2017209939A1/en not_active Ceased
- 2017-05-16 AR ARP170101300A patent/AR108489A1/es unknown
-
2018
- 2018-11-06 PH PH12018502334A patent/PH12018502334A1/en unknown
- 2018-11-20 IL IL263157A patent/IL263157A/en unknown
- 2018-11-27 CO CONC2018/0012857A patent/CO2018012857A2/es unknown
- 2018-11-29 CL CL2018003403A patent/CL2018003403A1/es unknown
- 2018-11-30 NI NI201800127A patent/NI201800127A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517497A5 (enExample) | ||
| JP2017536401A5 (enExample) | ||
| JP2017536398A5 (enExample) | ||
| HRP20211140T1 (hr) | Pripravci protiv raka | |
| JP2017536407A5 (enExample) | ||
| HRP20201902T1 (hr) | Pripravci protiv raka | |
| AR078499A1 (es) | Composiciones de corticosteroides de administracion oral | |
| JP2013199488A5 (enExample) | ||
| JP2019108366A5 (enExample) | ||
| CN117120034A (zh) | 阿比特龙前药 | |
| HRP20170313T1 (hr) | Kombinacije lijekova za liječenje duchenne mišićne distrofije | |
| JPH05501705A (ja) | 炎症性腸疾患処置用経口組成物 | |
| JP2019081792A5 (enExample) | ||
| JP2018504443A5 (enExample) | ||
| RU2011108220A (ru) | Кристаллические микрочастицы действующего вещества, способ их изготовления и их применение в лекарственных средствах | |
| CN102579367B (zh) | 托吡酯缓释药物组合物、其制备方法及用途 | |
| CN103889455B (zh) | 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂 | |
| BR112017027229B1 (pt) | Grânulos contendo estetrol secos, unidade de dosagem compreendendo grânulos, processo de preparação e seus usos | |
| CN103919735B (zh) | 一种盐酸坦索罗辛缓释微丸及其制备方法 | |
| ES2202528T3 (es) | Composiciones farmaceuticas de liberacion controlada para la administracion oral que contienen nifedipina como principio activo. | |
| JP2008534533A5 (enExample) | ||
| Roy et al. | Composite alginate hydrogel microparticulate delivery system of zidovudine hydrochloride based on counter ion induced aggregation | |
| JP2021505669A5 (enExample) | ||
| CN105078997A (zh) | 一种利伐沙班药用组合物及其制备方法 | |
| RU2015141792A (ru) | Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя |